These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12597948)

  • 1. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer.
    Shariat SF; Kim J; Nguyen C; Wheeler TM; Lerner SP; Slawin KM
    Urology; 2003 Feb; 61(2):359-64. PubMed ID: 12597948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
    Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
    Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.
    Shariat SF; Lamb DJ; Kattan MW; Nguyen C; Kim J; Beck J; Wheeler TM; Slawin KM
    J Clin Oncol; 2002 Feb; 20(3):833-41. PubMed ID: 11821468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of insulin-like growth factor (IGF) binding protein-2 to IGF-binding protein-3 ratio in patients undergoing radical cystectomy for invasive transitional cell carcinoma of the bladder.
    Miyake H; Hara I; Yamanaka K; Muramaki M; Eto H
    BJU Int; 2005 May; 95(7):987-91. PubMed ID: 15839919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy.
    Matsumoto K; Shariat SF; Casella R; Wheeler TM; Slawin KM; Lerner SP
    J Urol; 2003 Dec; 170(6 Pt 1):2248-52. PubMed ID: 14634390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.
    Andrews B; Shariat SF; Kim JH; Wheeler TM; Slawin KM; Lerner SP
    J Urol; 2002 Mar; 167(3):1475-81. PubMed ID: 11832773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene.
    Safarinejad MR; Shafiei N; Safarinejad SH
    Arch Toxicol; 2011 Oct; 85(10):1209-18. PubMed ID: 21347663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy.
    Moschini M; Morlacco A; Briganti A; Hu B; Colombo R; Montorsi F; Frank I; Daneshmand S; Karnes RJ
    Eur Urol Focus; 2018 Mar; 4(2):245-251. PubMed ID: 28753820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate.
    Frazier HA; Robertson JE; Dodge RK; Paulson DF
    Cancer; 1993 Jun; 71(12):3993-4001. PubMed ID: 8508365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate.
    Thrasher JB; Frazier HA; Robertson JE; Dodge RK; Paulson DF
    Cancer; 1994 Mar; 73(6):1708-15. PubMed ID: 8156499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma.
    Shariat SF; Kim JH; Andrews B; Kattan MW; Wheeler TM; Kim IY; Lerner SP; Slawin KM
    Cancer; 2001 Dec; 92(12):2985-92. PubMed ID: 11753975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.
    Steven K; Poulsen AL
    J Urol; 2007 Oct; 178(4 Pt 1):1218-23; discussion 1223-4. PubMed ID: 17698113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of plasma osteopontin levels in patients with bladder urothelial carcinomas.
    Zhao L; Wang Y; Qu N; Huang C; Chen L
    Mol Diagn Ther; 2012 Oct; 16(5):311-6. PubMed ID: 23055388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study.
    Grimm T; Buchner A; Schneevoigt B; Kretschmer A; Apfelbeck M; Grabbert M; Jokisch JF; Stief CG; Karl A
    World J Urol; 2016 May; 34(5):703-8. PubMed ID: 26376992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
    Laukhtina E; Schuettfort VM; D'Andrea D; Pradere B; Mori K; Quhal F; Sari Motlagh R; Mostafaei H; Katayama S; Grossmann NС; Rajwa P; Zeinler F; Abufaraj M; Moschini M; Zimmermann K; Karakiewicz PI; Fajkovic H; Scherr D; Compérat E; Nyirady P; Rink M; Enikeev D; Shariat SF
    Mol Carcinog; 2022 Jan; 61(1):5-18. PubMed ID: 34587660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.
    Yu H; Nicar MR; Shi R; Berkel HJ; Nam R; Trachtenberg J; Diamandis EP
    Urology; 2001 Mar; 57(3):471-5. PubMed ID: 11248622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy.
    Shariat SF; Bergamaschi F; Adler HL; Nguyen C; Kattan MW; Wheeler TM; Slawin KM
    Urology; 2000 Sep; 56(3):423-9. PubMed ID: 10962307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy.
    Herr HW
    Urology; 2003 Jan; 61(1):105-8. PubMed ID: 12559278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncologic outcomes for lymph node-positive urothelial carcinoma patients treated with robot assisted radical cystectomy: with mean follow-up of 3.5 years.
    Mmeje CO; Nunez-Nateras R; Nielsen ME; Pruthi RS; Smith A; Wallen EM; Humphreys MR; Woods ME; Castle EP
    Urol Oncol; 2013 Nov; 31(8):1621-7. PubMed ID: 22534088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.